| Time | Session |
|---|---|
|
08:30
13:00
|
Function Room 8, Ground Mezzanine Floor
|
| Time | Session |
|---|---|
|
08:00
08:30
|
APSR’s Leadership in Advancing Respiratory Medicine and Sciences in Asia
Established in 1986 to advance respiratory medicine and combat respiratory diseases in the Asia-Pacific, the Asian Pacific Society of Respirology (APSR) has grown into a major international society and a Founding Member of the Forum of International Respiratory Societies (FIRS). The APSR’s mission is to advance and disseminate knowledge of the respiratory system in health and disease across the Asia-Pacific and globally, aiming to bridge regional healthcare disparities and elevate research, education, and clinical practice. Guided by its vision to reshape the future of respiratory medicine through innovative, patient-centered, equitable, and sustainable care, the Society promotes collaboration among researchers and clinicians to provide optimal respiratory care tailored to the region’s diverse healthcare infrastructures and disease burdens. This lecture reviews the past year's achievements and key initiatives across five core pillars: hosting the annual APSR Congress, publishing official journals (Respirology and Respirology Case Reports), nurturing early-career researchers through education and fellowships, leading Assembly and Section activities, and advancing global advocacy and international partnerships.
A defining feature of the APSR is its "en bloc" society membership system. By integrating national respiratory societies, this strategy driven rapid expansion, rendering the APSR the largest respiratory society in the region. This sheer scale grants the Society strong leverage in international negotiations and policy advocacy alongside global bodies such as the WHO, ATS, and ERS. The en bloc membership system has expanded the APSR's reach and strengthened collaboration among respiratory societies across the Asia-Pacific. Building on this foundation, the APSR aims to encourage greater individual member participation and raise awareness of benefits such as journal access, educational programs, and fellowships. Closer partnerships with national and regional societies, together with clearer communication of the APSR's achievements, will further strengthen members' sense of connection and shared purpose. These efforts will enhance membership value and support the Society's sustainable growth.
Ballroom 3, Lower Ground Floor
|
|
08:30
09:00
|
Mycobacterial Genomics: Potential for Pulmonary NTM Disease Management
Mycobacterial Genomics: Potential for Pulmonary NTM Disease Management
Toshiaki Kikuchi, MD, PhD
Niigata University Medical & Dental Hospital, Japan
Background and Aims
The incidence of pulmonary nontuberculous mycobacterial (NTM) disease is increasing worldwide, particularly in Japan, where Mycobacterium avium complex predominates. Some patients experience disease progression that requires antimicrobial treatment, whereas others remain stable without treatment for years. Because disease progression is difficult to predict, deciding when to start treatment remains challenging. We investigated whether the genomic characteristics of M. avium clinical isolates are associated with disease progression.
Methods
We performed whole-genome sequencing of 36 clinical M. avium isolates from patients with progressive (n = 25) or stable (n = 11) disease. Progressive disease was defined as initiation of treatment within 12 months of diagnosis, and stable disease as no treatment during this period. Comparative analyses included whole-genome alignment, phylogenetic analysis based on average amino acid identity (AAI), and single-nucleotide variant (SNV) analysis.
Results
Comparative genomic analysis identified a 1.4-Mb genomic inversion that distinguished two genomic types, type A and type non-A. All 15 type A isolates were from patients with progressive disease, whereas the 21 type non-A isolates were from patients with progressive (n = 10) or stable (n = 11) disease. Type A isolates also lacked genes adjacent to the inversion breakpoints, including the vapBC-5 toxin–antitoxin system, which may affect the regulation of bacterial growth. AAI-based phylogenetic analysis independently separated type A from type non-A isolates and revealed additional clusters associated with disease progression. Furthermore, SNV analysis of type non-A isolates identified variants associated with progression, including one in uvrB, a gene involved in DNA repair.
Conclusion
These findings suggest that genomic profiling of M. avium isolates may help predict disease progression and guide individualized treatment decisions in pulmonary NTM disease.
Keywords: Nontuberculous mycobacteria, Whole-genome sequencing, Disease progression
Reference: Tanaka K et al, Int J Infect Dis, 2026, 169, 108816.
Disclosure Statement: The presenting author has received honoraria or consultation fees from Insmed, KYORIN Pharmaceutical, and Janssen Pharmaceutical.
Ballroom 3, Lower Ground Floor
|
|
09:30
11:00
|
Ballroom 1, Lower Ground Floor
|
|
12:00
13:00
|
Sponsored by GlaxoSmithKline
Ballroom 2, Lower Ground Floor
|
|
14:00
15:00
|
Ballroom 3, Lower Ground Floor
|